TY - JOUR
T1 - Pharmacokinetics of oseltamivir according to trimester of pregnancy
AU - Greer, Laura G.
AU - Leff, Richard D.
AU - Rogers, Vanessa Laibl
AU - Roberts, Scott W.
AU - McCracken, George H.
AU - Wendel, George D.
AU - Sheffield, Jeanne S.
N1 - Funding Information:
Supported by University of Texas Southwestern Medical Center Department of Obstetrics and Gynecology and by Grant # 5-U10-HD046000-05 from National Institutes of Health .
Funding Information:
Publication of this article was supported by the Centers for Disease Control and Prevention and the Association of Maternal and Child Health Programs.
PY - 2011/6
Y1 - 2011/6
N2 - The purpose of this study was to determine pharmacokinetic parameters for oseltamivir in all trimesters of pregnancy. Thirty pregnant women, 10 per trimester, who were receiving oseltamivir phosphate (75 mg) were recruited to study first-dose pharmacokinetics. Plasma samples were obtained at 0, 0.5, 1, 2, 4, 8, and 12 hours after the first dose. Samples were analyzed for oseltamivir and oseltamivir carboxylate levels. With the use of a noncompartmental model, we estimated the area-under-the-curve, maximum concentration, time-to-maximum concentration, and half-life. There were no significant differences in the pharmacokinetics of oseltamivir by trimester, except for an increased half-life in the first trimester for oseltamivir phosphate and an increased maximum concentration in the third trimester for oseltamivir carboxylate. The levels of oseltamivir carboxylate that were observed were within the range that was needed to achieve inhibitory concentrations at 50% for pandemic H1N1. The pharmacokinetics of oseltamivir does not change significantly according to trimester of pregnancy.
AB - The purpose of this study was to determine pharmacokinetic parameters for oseltamivir in all trimesters of pregnancy. Thirty pregnant women, 10 per trimester, who were receiving oseltamivir phosphate (75 mg) were recruited to study first-dose pharmacokinetics. Plasma samples were obtained at 0, 0.5, 1, 2, 4, 8, and 12 hours after the first dose. Samples were analyzed for oseltamivir and oseltamivir carboxylate levels. With the use of a noncompartmental model, we estimated the area-under-the-curve, maximum concentration, time-to-maximum concentration, and half-life. There were no significant differences in the pharmacokinetics of oseltamivir by trimester, except for an increased half-life in the first trimester for oseltamivir phosphate and an increased maximum concentration in the third trimester for oseltamivir carboxylate. The levels of oseltamivir carboxylate that were observed were within the range that was needed to achieve inhibitory concentrations at 50% for pandemic H1N1. The pharmacokinetics of oseltamivir does not change significantly according to trimester of pregnancy.
KW - influenza
KW - oseltamivir
KW - pharmacokinetics
KW - pregnancy
UR - http://www.scopus.com/inward/record.url?scp=79958001276&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79958001276&partnerID=8YFLogxK
U2 - 10.1016/j.ajog.2011.03.005
DO - 10.1016/j.ajog.2011.03.005
M3 - Review article
C2 - 21492824
AN - SCOPUS:79958001276
SN - 0002-9378
VL - 204
SP - S89-S93
JO - American Journal of Obstetrics and Gynecology
JF - American Journal of Obstetrics and Gynecology
IS - 6 SUPPL.
ER -